The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 study of PHST001, an anti-CD24 monoclonal antibody, in adult patients with advanced relapsed and/or refractory solid tumors.
 
Ulka Vaishampayan
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb/Medarex; Exelixis; Janssen Oncology; Merck Serono; Novartis; Pfizer; Pfizer/Astellas; xencor
Research Funding - Bristol-Myers Squibb; Merck KGaA
 
Stephane Champiat
Stock and Other Ownership Interests - Avacta Life Sciences
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai Europe; Fresenius Kabi; Genmab; Janssen; Merck KGaA; Merck Serono; MSD; Novartis; Roche; SERVIER; Takeda
Consulting or Advisory Role - Alderaan Biotechnology; Amgen; AstraZeneca; Avacta Life Sciences; Bayer; BeiGene; BioCodex; BioNTech SE; Boehringer Ingelheim; Celanese; Compugen; Domain Therapeutics; Ellipses Pharma; GE Healthcare; Genmab; Guardant Health; Immunicom; Ipsen; Mariana Oncology; Mima Health; Nanobiotix; NextCure; Oncovita; PharmaMar; Pierre Fabre; Replimune; Seagen; Takeda; Tatum Bioscience; Tollys; UltraHuman8
Research Funding - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Boehringer Ingelheim; Bolt Biotherapeutics; Centessa Pharmaceuticals; Cytovation; Eisai/H3 Biomedicine; Exelixis; GlaxoSmithKline; ImCheck therapeutics; Immunocore; Kumquat Biosciences; Marengo Therapeutics; Molecular Partners; MSD; OncoC4; OSE Immunotherapeutics; Owkin; Pheast Therapeutics; Pierre Fabre; Replimune; Roche/Genentech; Sanofi; Seagen; Sotio; Transgene; Trutino Biosciences; Veracyte (Inst); VIR Biotechnology
Patents, Royalties, Other Intellectual Property - T-cell immunogens derived from anti-viral proteins and methods of using same WO2010039223A2
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GE Healthcare; Merck; MSD; OSE Immunotherapeutics; Roche; Sotio
 
Michael Cecchini
Stock and Other Ownership Interests - Parthenon Therapeutics
Honoraria - Abbvie; Agenus; Arcus Biosciences; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Cybrexa Therapeutics; Daiichi Sankyo/Astra Zeneca; DAVA Pharmaceuticals; Elevation Oncology; Incendia Therapeutics; Incyte; Loxo/Lilly; Macrogenics; Modifi Bio; Parabalis; Regeneron; Seagen; Taiho Oncology; Wren Therapeutics
 
Oliver Dorigo
Honoraria - Blueprint Medicines
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; GlaxoSmithKline; IMV; Merck; PSI CRO Deutschland; R-Pharm
Speakers' Bureau - ImmunoGen
Research Funding - AstraZeneca (Inst); BioEclipse Therapeutics (Inst); EMD Serono (Inst); Genentech (Inst); IMV (Inst); Millennium (Inst); Novartis (Inst); PharmaMar (Inst)
 
Anthony El-Khoueiry
Honoraria - Abbvie; Agenus; AstraZeneca/MedImmune; Bristol-Myers Squibb; Daiichi Sankyo Brazil; EISAI; Elevar Therapeutics; Exelixis; Janssen Oncology; Jazz Pharmaceuticals; Merck; Qurient; Roche/Genentech; Senti Biosciences; SERVIER; TERUMO
Consulting or Advisory Role - Agenus; AstraZeneca/MedImmune; Bristol-Myers Squibb; Eisai; Elevar Therapeutics; Exelixis; Genentech; Janssen; Jazz Pharmaceuticals; Merck; Qurient; Roche; Senti Biosciences; SERVIER; TERUMO
Research Funding - Astex Pharmaceuticals; AstraZeneca; Auransa; Fulgent Genetics
Travel, Accommodations, Expenses - Affimed Therapeutics
 
Gini Fleming
Research Funding - Abbvie (Inst); Artios (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Celldex (Inst); Compugen (Inst); Compugen (Inst); Corcept Therapeutics (Inst); Duality Biologics (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); K-Group Beta (Inst); Merck (Inst); Molecular Templates (Inst); P{fizer (Inst); Pheast Therapeutics (Inst); Roche (Inst); Sanofi (Inst); Sermonix Pharmaceuticals (Inst); Systimmune (Inst)
 
Niharika Mettu
Research Funding - Adanate (Inst); Amgen (Inst); Biohaven Pharmaceuticals (Inst); BioNTech (Inst); Jazz Pharmaceuticals (Inst); Leap Health (Inst); MediLink (Inst); Merck (Inst); MOMA Therapeutics (Inst); Pfizer (Inst); PMV Pharma (Inst); Revolution Medicines (Inst); Sapience Therapeutics (Inst); Seagen (Inst)
 
Michael Dennis
Employment - Dana Farber Cancer Hospital
Honoraria - Coherus Biosciences
Consulting or Advisory Role - Corbus Pharmaceuticals, Inc.
Speakers' Bureau - Dr. Reddy's Laboratories
Travel, Accommodations, Expenses - Dr. Reddy's Laboratories
 
Elizabeth Davis
Honoraria - MJH Life Sciences
Consulting or Advisory Role - Aadi; Deciphera
Speakers' Bureau - Physicans' Education Resource
Research Funding - Actuate Therapeutics (Inst); Cogent Biosciences (Inst); Cornerstone Pharmaceuticals (Inst); InhibRx (Inst); Karyopharm Therapeutics (Inst); Pheast Therapeutics (Inst); SERVIER (Inst); TopAlliance BioSciences Inc (Inst)
Travel, Accommodations, Expenses - Spring Works
 
Jennifer Yinuo Cao
Employment - Pheast Therapeutics
Stock and Other Ownership Interests - Pheast Therapeutics
 
Suzana Kahn
Employment - Pheast Therapeutics
Stock and Other Ownership Interests - Pheast Therapeutics
 
Susan Luebbe
Employment - Pheast Therapeutics
Stock and Other Ownership Interests - Pheast Therapeutics
 
Andrew Ferguson
Employment - Pheast Therapeutics
Stock and Other Ownership Interests - Pheast Therapeutics
 
Raphaël Rousseau
Employment - Pheast Therapeutics
Stock and Other Ownership Interests - Pheast Therapeutics
 
Kyriakos Papadopoulos
Consulting or Advisory Role - AADi; Turning Point Therapeutics
Research Funding - 3D Medicines (Inst); Abbvie (Inst); Alnylam (Inst); Amgen (Inst); Anheart Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Biontech (Inst); Bristol-Myers Squibb/Celgene (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); F-star (Inst); Frontier Medicines (Inst); Genmab (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Kezar Life Sciences (Inst); Lilly (Inst); Linnaeus Therapeutics (Inst); MabSpace Biosciences (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Monte Rosa Therapeutics (Inst); Parabilis Medicines (Inst); Pfizer (Inst); PharmaMar (Inst); Regeneron (Inst); Revolution Medicines (Inst); Sensei Biotherapeutics (Inst); Storm Therapeutics (Inst); Syros Pharmaceuticals (Inst); Tempest Therapeutics (Inst); Treadwell Therapeutics (Inst)